Our Blog:

30 years of cell culture excellence

Author: Biological Industries

BI Announces Poster Presentation at International Society for Cell Therapy Annual Meeting in Singapore

Dr. Mira Genser-Nir to Present Poster at ISCT 2016 on Novel Set of Serum-Free, Xeno-Free Differentiation Media May 23, 2016 KIBBUTZ BEIT HAEMEK, Israel & CROMWELL, Conn.–(BUSINESS WIRE)–Biological Industries (“BI”; www.bioind.com), a leading developer and manufacturer of cell culture media, molecular biology tools, human cytogenetics media, and custom media manufacturing services, is participating and making a poster presentation at ISCT 2016, the annual meeting of the International Society for Cellular Therapy, 25-28 May, in Singapore. The poster presentation, “A Novel Set of Serum-Free, Xeno-Free Differentiation Media for Adipogenesis, Osteogenesis and Chondrogenesis of Human Mesenchymal Stem Cells from Various Tissue...

Read More

European Field Application Specialist for Stem Cell Products

Biological Industries (BI) is very pleased to announce the appointment of Suzanne Badoux as our new European Field Application Specialist focusing on our technically supporting our stem cell products and services. Along with the launch of Biological Industries USA (BI USA), a new division headquartered in the United States, the appointment of an European Field Application Specialist is part of BI planned growth strategy, and provides technical support for scientists in Europe. Suzanne gained her MSc in Medical Biology at UNIL, The University of Lausanne, Switzerland She has also now completed an intensive training at the BI facility in Beit Haemek, Israel, where she spent a total of 3 months in  production, R&D, customer services and Marketing departments. We are very confident that Suzanne’s appointment will help researchers around Europe have in-person support, and easy, direct access to our dedicated technical experts and collaborations with our R&D scientists....

Read More

Biological Industries Expands to the United States

Biological Industries expands to the United States, providing innovative research technology to the U.S. life sciences market CROMWELL, CT, USA & Kibbutz Beit Haemek, Israel, October 15, 2015 – Biological Industries (http://www.bioind.com/), a leading developer and manufacturer of cell culture media, molecular biology tools, human cytogenetics media, and custom media manufacturing services, announced today it will be expanding its operations to the United States. The company, which prides itself with over 30 years of cell culture media development expertise, state-of-the-art cGMP facilities, and key partnerships with some of the worlds’ leading scientists, will launch Biological Industries USA, Inc. (BI-USA)...

Read More

BI-USA featured in Hartford Business Journal

Cultured Growth: CT’s economic, cultural siren song attracts Israeli firms Article by: GREGORY SEAY, Photograph by STEVE LASCHEVER Connecticut’s coordinated recruiting efforts to lure more international firms to the state are resonating loudest among nascent technology firms in Israel, observers say. At least two Israeli technology firms have opened doors in this state in recent years, and dozens more are exploring opportunities to lease or buy real estate and employ workers to ply the broader U.S. market with their products and services. One, Biological Industries, last fall opened in Cromwell, where it stores and distributes cultures used to grow...

Read More

Biological Industries announces DMF now available for MSC NutriStem® XF

As part of our ongoing efforts to bring you added value in terms of innovation, quality and regulatory aspects, Biological Industries (BI) announces acceptance by the FDA of a Drug Master File (DMF) for our MSC NutriStem® XF Basal Medium and Supplement. BI’s defined, xeno-free, serum-free medium, designed to support the isolation and growth of human mesenchymal stem cells. MSC NutriStem® XF is considered in regulatory aspects as an “Ancillary Material” meaning; a material used in the process but is not part of the final product. The USP defines the requirements of ancillary materials in a general monograph USP<1043> “Ancillary Materials for Cell-,Gene-, and Tissue-Engineered Products”. In accordance to the USP Risk classification (4 tiers), the product is characterized as low- risk. Drug Master Files are confidential documents submitted to the FDA which outline, in detail, manufacturing and procedural details for drugs or biological materials used in animals or humans. In order to reference information regarding MSC NutriStem® in DMF number 29469, please contact us by filling out the following authorization request in accordance with the instruction in the document Requesting Letter of Authorization...

Read More

Follow Us